State Street’s AbbVie ABBV Stock Holding History

State Street’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$17.7B	Buy	81,217,516 +276,585	+0.3%	+$61.4M	0.61%	23
2025 Q4	$18.5B	Buy	80,940,931 +1,119,274	+1%	+$255M	0.62%	20
2025 Q3	$18.5B	Sell	79,821,657 -202,472	-0.3%	-$41.2M	0.64%	22
2025 Q2	$14.9B	Buy	80,024,129 +61,162	+0.1%	+$11.4M	0.56%	27
2025 Q1	$16.8B	Buy	79,962,967 +341,480	+0.4%	+$66.4M	0.69%	22
2024 Q4	$14.1B	Buy	79,621,487 +553,552	+0.7%	+$102M	0.56%	26
2024 Q3	$15.6B	Buy	79,067,935 +1,267,685	+2%	+$237M	0.64%	23
2024 Q2	$13.3B	Sell	77,800,250 -170,408	-0.2%	-$28.2M	0.58%	24
2024 Q1	$14.2B	Sell	77,970,658 -230,208	-0.3%	-$39.7M	0.63%	23
2023 Q4	$12.1B	Buy	78,200,866 +237,936	+0.3%	+$34.7M	0.59%	24
2023 Q3	$11.6B	Sell	77,962,930 -219,637	-0.3%	-$32.2M	0.64%	23
2023 Q2	$10.5B	Buy	78,182,567 +1,156,130	+2%	+$170M	0.55%	26
2023 Q1	$12.3B	Sell	77,026,437 -1,042,817	-1%	-$159M	0.69%	21
2022 Q4	$12.6B	Buy	78,069,254 +582,937	+0.8%	+$89.4M	0.74%	20
2022 Q3	$10.4B	Buy	77,486,317 +366,695	+0.5%	+$52.6M	0.66%	22
2022 Q2	$11.8B	Sell	77,119,622 -918,574	-1%	-$140M	0.71%	21
2022 Q1	$12.7B	Sell	78,038,196 -1,319,509	-2%	-$192M	0.63%	22
2021 Q4	$10.7B	Buy	79,357,705 +2,597,076	+3%	+$307M	0.51%	31
2021 Q3	$8.28B	Buy	76,760,629 +797,325	+1%	+$91.1M	0.44%	40
2021 Q2	$8.56B	Buy	75,963,304 +467,356	+0.6%	+$52.6M	0.45%	38
2021 Q1	$8.17B	Sell	75,495,948 -2,666,116	-3%	-$285M	0.47%	39
2020 Q4	$8.38B	Sell	78,162,064 -46,397	-0.1%	-$4.46M	0.51%	35
2020 Q3	$6.85B	Sell	78,208,461 -1,516,594	-2%	-$143M	0.47%	43
2020 Q2	$7.83B	Buy	79,725,055 +11,496,437	+17%	+$1.01B	0.57%	34
2020 Q1	$5.2B	Sell	68,228,618 -592,121	-0.9%	-$50.4M	0.45%	44
2019 Q4	$6.09B	Buy	68,820,739 +37,212	+0.1%	+$3.09M	0.42%	46
2019 Q3	$5.21B	Buy	68,783,527 +1,516,048	+2%	+$104M	0.39%	46
2019 Q2	$4.89B	Buy	67,267,479 +1,068,958	+2%	+$84M	0.36%	52
2019 Q1	$5.33B	Buy	66,198,521 +1,931,978	+3%	+$158M	0.42%	43
2018 Q4	$5.92B	Buy	64,266,543 +765,637	+1%	+$67.3M	0.54%	36
2018 Q3	$6.01B	Buy	63,500,906 +2,699,653	+4%	+$256M	0.46%	40
2018 Q2	$5.63B	Sell	60,801,253 -2,794,830	-4%	-$273M	0.47%	42
2018 Q1	$6.02B	Sell	63,596,083 -3,195,801	-5%	-$351M	0.51%	41
2017 Q4	$6.46B	Sell	66,791,884 -1,456,010	-2%	-$137M	0.52%	39
2017 Q3	$6.06B	Sell	68,247,894 -3,153,509	-4%	-$240M	0.52%	40
2017 Q2	$5.18B	Sell	71,401,403 -1,568,127	-2%	-$105M	0.46%	44
2017 Q1	$4.75B	Buy	72,969,530 +1,696,042	+2%	+$107M	0.42%	46
2016 Q4	$4.46B	Buy	71,273,488 +2,763,770	+4%	+$169M	0.42%	46
2016 Q3	$4.32B	Buy	68,509,718 +1,564,198	+2%	+$101M	0.44%	47
2016 Q2	$4.14B	Sell	66,945,520 -229,621	-0.3%	-$14M	0.45%	47
2016 Q1	$3.84B	Sell	67,175,141 -2,087,885	-3%	-$116M	0.41%	51
2015 Q4	$4.1B	Buy	69,263,026 +1,181,531	+2%	+$68.1M	0.45%	47
2015 Q3	$3.7B	Sell	68,081,495 -3,822,863	-5%	-$249M	0.43%	50
2015 Q2	$4.83B	Buy	71,904,358 +2,035,276	+3%	+$133M	0.52%	36
2015 Q1	$4.09B	Sell	69,869,082 -1,659,591	-2%	-$100M	0.42%	53
2014 Q4	$4.68B	Buy	71,528,673 +2,064,110	+3%	+$130M	0.47%	46
2014 Q3	$4.01B	Sell	69,464,563 -486,944	-0.7%	-$27M	0.43%	48
2014 Q2	$3.95B	Buy	69,951,507 +2,056,902	+3%	+$108M	0.43%	46
2014 Q1	$3.49B	Sell	67,894,605 -3,890,220	-5%	-$197M	0.4%	52
2013 Q4	$3.79B	Buy	71,784,825 +694,888	+1%	+$34.2M	0.42%	46
2013 Q3	$3.18B	Buy	71,089,937 +99,374	+0.1%	+$4.41M	0.39%	50
2013 Q2	$2.93B	Buy	+70,990,563	New	+$3.1B	0.38%	51

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

State Street's ABBV Position: Q1 2026 in Review

State Street increased its AbbVie (ABBV) stake by 0.34% in Q1 2026, buying an estimated $61.4M and bringing the position to 81,217,516 shares worth $17.7B. The position accounts for 0.61% of the portfolio, ranked #23.

State Street first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $18.5B in Q4 2025. 4,078 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

State Street held 81,217,516 shares of AbbVie worth $17.7B as of Q1 2026.
State Street bought 276,585 AbbVie shares in Q1 2026, an estimated $61.4M.
AbbVie made up 0.61% of State Street's portfolio in Q1 2026, its #23 holding.
State Street first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
State Street's AbbVie position peaked at $18.5B in Q4 2025.
4,078 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.